Mezagitamab (TAK-079) is a IgG1lambda anti-CD38 monoclonal antibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP)[1][2][3].
Molecular Weight:
(143.7 kDa)
Purity:
99.79
CAS Number:
[2227490-52-8]
Target:
Apoptosis,CD38
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted